Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

OCTOBER 18, 2019

Pharmatest attends AACR-NCI-EORTC and SITC 2019 events

Pharmatest Services attends AACR-NCI-EORTC Conference in Boston, MA on October 26 –30 and SITC Annual Meeting 2019 in National Harbor, MD on November 7–10. In both events, Pharmatest publishes novel models and emerging scientific findings from preclinical immuno-oncology studies.

In the AACR-NCI-EORTC conference Pharmatest has the following poster presentations:

  • Establishment of a novel prostate cancer bone metastasis model in humanized mice and early efficacy results of pembrolizumab. Late-breaking poster A148 on Sunday, October 27.
  • Establishment of primary tumor models of TNBC and ER+/HER2- breast cancer in humanized mice and validation of pembrolizumab efficacy. Poster B143 on Monday, October 28.
  • Lack of immunotherapy efficacy in a syngeneic bone metastasis model of triple-negative breast cancer. Poster B144 on Monday, October 28.

In the SITC Annual Meeting 2019 Pharmatest has the following poster presentation:

  • Pitfalls in preclinical development of immunotherapies for ER+ breast cancer: estrogen as an immunomodulator potentially influencing pembrolizumab efficacy in a breast cancer model in humanized mice. Poster P284, presented on Saturday, November 9.

Pharmatest welcomes everyone to visit our posters in the events. If you would like to schedule a meeting with our representatives during the events click here.